根据AI大模型测算南京新百后市走势。短期趋势看，连续3日被主力资金减仓。主力没有控盘。中期趋势方面，下方累积一定获利筹码。近期该股有吸筹现象，但吸筹力度不强。舆情分析来看，1家机构预测目标均价8.00，高于当前价20.85%。目前市场情绪极度悲观。

近来，南京新百的股市表现引发了投资者的广泛关注。在10月29日，这家公司的股票出现了3.27%的下跌，成交额达到1.76亿元，换手率为2.28%。尽管当前股价有所下滑，但市场对其未来前景的讨论仍然激烈。本文将深入分析南京新百的各项数据与业务动态，探讨其后市是否还有机会。 首先，我们来了解一下南京新百当前的市场表现。根据最新的数据显示，该公司的总市值为87.50亿元，短期趋势表明主力资金并未有明显的 ...

The April 29 approval of Seattle-based Dendreon's prostate cancer vaccine, Provenge (sipuleucel-T), is being hailed as a victory for cancer immunotherapy. For Dendreon, the US Food and Drug ...

Provenge (sipuleucel-T) is an autologous cellular immunotherapy, which involves removing immune cells from a patient's blood, priming them to recognise prostate cancer, and then returning them to ...

截至6月30日，南京新百股东户数4.40万，较上期增加7.35%；人均流通股26486股，较上期减少6.84%。2024年1月-6月，南京新百实现营业收入32.51亿元，同比增长0.40%；归母净利润1.65亿元，同比减少48.65%。 分红方面，南京新百A股上市后累计派现10.96亿元。近三年，累计派现1.07亿元。

In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration ...

Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung ...

Though it may seem like something from the future, these five cancer vaccines are available now. Here, more details on who is eligible for each.

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

One prostate cancer vaccine, Provenge, was shown to lengthen the life of men with widespread disease. It also is a dendritic vaccine -- dendritic cells are taken from a man, "taught" to recognize ...